

Columbia University and Mitogen Announce Partnership to Prepare for Clinical Trials of Regenerative Meniscus Implant

First-in-class implant produced using tissue regeneration technology

New York & Indianapolis — Following the June 9, 2015 Future of Urban Innovation: Startups conference in New York City, Columbia University and Mitogen announce a partnership to attract investment for its first-in-class implant that regenerates the body's own tissue. Mitogen's novel implant, manufactured using a 3D printer, is made of a biodegradable material infused with recombinant human proteins. This scaffold induces the body to repair its own tissue, enabling a knee joint to regrow its own meniscus.

"At present there's little that orthopedists can do to regenerate a torn knee meniscus," said Jeremy Mao, DDS, PhD, the Edwin S. Robinson Professor of Dentistry (in Orthopedic Surgery) at Columbia University Medical Center, and co-founder of Mitogen, Inc., a New York and Indianapolis based medical device company raising capital to commercialize the device. "Removal of a torn meniscus leaves the knee without the natural shock absorber, cartilage, greatly increasing the risk of osteoarthritis." Scientists at Columbia have successfully completed animal trials in sheep, which have a meniscus very similar to humans. "We are encouraged by the results," said Nelson Scharadin, co-founder & CEO of Mitogen. "This is one of several bioengineering applications we are exploring for the technology."

"The research demonstrates the potential for an innovative approach to meniscus regeneration," said Dr. Scott Rodeo, orthopedic surgeon at Hospital for Special Surgery, and co-founder of Mitogen. "This would potentially be applicable to the many patients who undergo meniscus removal each year."



###

Mitogen

Mitogen is a medical device company whose mission is to advance this product into human clinical trials, beginning 1H 2016, and co-develop and commercialize additional products in the future. Additional product applications can be viewed on the company's website at www.mitogeninc.com

Columbia Technology Ventures, Columbia University

A leading academic and research university, Columbia University continually seeks to advance the frontiers of knowledge and to foster a campus community deeply engaged in understanding and addressing the complex global issues of our time. Columbia University's technology transfer office, Columbia Technology Ventures, manages Columbia's intellectual property portfolio and serves as the university's gateway for companies and entrepreneurs seeking novel technology solutions. Our core mission is to facilitate the transfer of inventions from academic research to outside organizations for the benefit of society on a local, national and global basis. For more information on Columbia Technology Ventures, please visit techventures.columbia.edu.

For more information, press only:

Nelson Scharadin
317-793-8222
nelson@mitogeninc.com

For more information on Mitogen:

www.mitogeninc.com